MX2019001453A - Metodos mejorados para producir genotecas de polinucleotidos en virus vacuna/ celulas eucariotas. - Google Patents
Metodos mejorados para producir genotecas de polinucleotidos en virus vacuna/ celulas eucariotas.Info
- Publication number
- MX2019001453A MX2019001453A MX2019001453A MX2019001453A MX2019001453A MX 2019001453 A MX2019001453 A MX 2019001453A MX 2019001453 A MX2019001453 A MX 2019001453A MX 2019001453 A MX2019001453 A MX 2019001453A MX 2019001453 A MX2019001453 A MX 2019001453A
- Authority
- MX
- Mexico
- Prior art keywords
- vaccinia virus
- eukaryotic cells
- improved methods
- polynucleotide libraries
- interest
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 102000040430 polynucleotide Human genes 0.000 title abstract 3
- 108091033319 polynucleotide Proteins 0.000 title abstract 3
- 239000002157 polynucleotide Substances 0.000 title abstract 3
- 241000700618 Vaccinia virus Species 0.000 title abstract 2
- 210000003527 eukaryotic cell Anatomy 0.000 title 1
- 238000010276 construction Methods 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 abstract 1
- 229960001225 rifampicin Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1082—Preparation or screening gene libraries by chromosomal integration of polynucleotide sequences, HR-, site-specific-recombination, transposons, viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1086—Preparation or screening of expression libraries, e.g. reporter assays
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1093—General methods of preparing gene libraries, not provided for in other subgroups
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
- C40B50/06—Biochemical methods, e.g. using enzymes or whole viable microorganisms
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Computational Biology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Esta descripción proporciona un método mejorado para construir una genoteca de polinucleotidos de interés en un poxvirus, por ejemplo, un sistema del vector del virus vacuna, en donde los polinucleotidos de interés codifican los polipéptidos de interés; el método comprende construir la genoteca en presencia de un inhibidor del ensamble de poxvirus, por ejemplo, rifampicina, que permite la construcción de las genotecas con complejidad y diversidad mas elevadas que los métodos anteriores.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662370009P | 2016-08-02 | 2016-08-02 | |
PCT/US2017/044688 WO2018026715A1 (en) | 2016-08-02 | 2017-07-31 | Improved methods for producing polynucleotide libraries in vaccinia virus/eukaryotic cells |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2019001453A true MX2019001453A (es) | 2019-06-20 |
Family
ID=61073907
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019001453A MX2019001453A (es) | 2016-08-02 | 2017-07-31 | Metodos mejorados para producir genotecas de polinucleotidos en virus vacuna/ celulas eucariotas. |
Country Status (14)
Country | Link |
---|---|
US (3) | US20190169606A1 (es) |
EP (1) | EP3494131A4 (es) |
JP (2) | JP7128177B2 (es) |
KR (1) | KR102449406B1 (es) |
CN (1) | CN109563143A (es) |
AU (1) | AU2017306062B2 (es) |
BR (1) | BR112019001944A2 (es) |
CA (1) | CA3032512A1 (es) |
IL (1) | IL264343B2 (es) |
MX (1) | MX2019001453A (es) |
RU (1) | RU2747557C2 (es) |
SG (1) | SG11201900595YA (es) |
WO (1) | WO2018026715A1 (es) |
ZA (1) | ZA201901286B (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6059013B2 (ja) | 2009-05-08 | 2017-01-11 | バクシネックス インコーポレーティッド | 抗cd100抗体およびこれを使用するための方法 |
SG11201401458UA (en) | 2011-10-11 | 2014-07-30 | Vaccinex Inc | Use of semaphorin-4d binding molecules for modulation of blood brain barrier permeability |
US9708601B2 (en) | 2012-04-26 | 2017-07-18 | Vaccinex, Inc. | Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus |
CA2916245C (en) | 2013-06-25 | 2023-01-24 | Vaccinex, Inc. | Use of semaphorin-4d inhibitory molecules in combination with an immune modulating therapy to inhibit tumor growth and metastases |
NZ630892A (en) | 2013-10-21 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treating neurodegenerative disorders |
MX2018012818A (es) | 2016-04-22 | 2019-07-04 | Vaccinex Inc | Presentacion de proteina de membrana integral en viriones envueltos extracelulares de poxvirus. |
IL264343B2 (en) * | 2016-08-02 | 2024-05-01 | Vaccinex Inc | Improved methods for generating polynucleotide libraries in cowpox/eukaryotic cells |
Family Cites Families (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
IL87737A (en) | 1987-09-11 | 1993-08-18 | Genentech Inc | Method for culturing polypeptide factor dependent vertebrate recombinant cells |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
EP0502036B1 (en) | 1989-11-22 | 1995-12-20 | Genentech, Inc. | Latency associated peptide and uses therefor |
DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
US5445953A (en) | 1991-08-26 | 1995-08-29 | Immuno Aktiengesellschaft | Direct molecular cloning of a modified poxvirus genome |
AU694519B2 (en) | 1994-04-29 | 1998-07-23 | Immuno Aktiengesellschaft | Recombinant poxviruses with foreign polynucleotides in essential regions |
US6576754B2 (en) | 1995-11-09 | 2003-06-10 | Dana-Farber Cancer Institute | CD100 antigen and uses therefor |
US6872518B2 (en) | 1997-09-22 | 2005-03-29 | University Of Rochester | Methods for selecting polynucleotides encoding T cell epitopes |
DE69839970D1 (de) | 1998-11-10 | 2008-10-16 | Univ Rochester | Methoden zu herstellung von genbanken |
EP1268763A2 (en) * | 2000-03-28 | 2003-01-02 | University Of Rochester | Methods of producing a library and methods of selecting polynucleotides |
CA2341356C (en) | 2000-04-14 | 2011-10-11 | Transgene S.A. | Poxvirus with targeted infection specificity |
AU2001297872B2 (en) * | 2000-11-17 | 2006-11-09 | University Of Rochester | In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells |
WO2002086096A2 (en) * | 2001-01-23 | 2002-10-31 | University Of Rochester Medical Center | Methods of producing or identifying intrabodies in eukaryotic cells |
AU2002255495A1 (en) * | 2001-02-02 | 2002-08-19 | University Of Rochester | Methods of identifying regulator molecules |
EP1413316A1 (en) | 2002-09-27 | 2004-04-28 | Bruno Robert | Bifunctional conjugates or fusion proteins |
US9809654B2 (en) | 2002-09-27 | 2017-11-07 | Vaccinex, Inc. | Targeted CD1d molecules |
EP1442749A1 (en) | 2003-01-31 | 2004-08-04 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Use of anti-CD100 antibodies for the treatment and the diagnosis of inflammatory disorder affecting the central nervous system |
WO2005055936A2 (en) | 2003-12-04 | 2005-06-23 | Vaccinex, Inc. | Methods of killing tumor cells by targeting internal antigens exposed on apoptotic tumor cells |
US20050266425A1 (en) | 2003-12-31 | 2005-12-01 | Vaccinex, Inc. | Methods for producing and identifying multispecific antibodies |
KR101377116B1 (ko) | 2004-08-27 | 2014-03-24 | 알버트 아인슈타인 컬리지 오브 메디신 오브 예쉬바 유니버시티 | 면역 및 자가면역의 조절제로서의 세라마이드 유도체 |
US8022043B2 (en) | 2004-08-27 | 2011-09-20 | Albert Einstein College Of Medicine Of Yeshiva University | Ceramide derivatives as modulators of immunity and autoimmunity |
AU2006232310B9 (en) * | 2005-04-06 | 2011-07-21 | Ibc Pharmaceuticals, Inc. | Improved stably tethered structures of defined compositions with multiple functions or binding specificities |
RU2311927C2 (ru) * | 2005-08-15 | 2007-12-10 | Федеральное государственное унитарное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека" | КОМБИНАТОРНАЯ ФАГМИДНАЯ БИБЛИОТЕКА ОДНОЦЕПОЧЕЧНЫХ АНТИТЕЛ ЧЕЛОВЕКА, ОБОГАЩЕННАЯ АНТИТЕЛАМИ ПРОТИВ ВИРУСА ОСПОВАКЦИНЫ, РЕКОМБИНАНТНАЯ ФАГМИДНАЯ ДНК pHEN-2A8, СОДЕРЖАЩАЯ УНИКАЛЬНЫЙ ГЕН ОДНОЦЕПОЧЕЧНОГО АНТИТЕЛА ЧЕЛОВЕКА, СПОСОБНОГО НЕЙТРАЛИЗОВАТЬ ВИРУС ОСПОВАКЦИНЫ И ВИРУС ОСПЫ КОРОВ, И ИСКУССТВЕННОЕ ОДНОЦЕПОЧЕЧНОЕ АНТИТЕЛО ЧЕЛОВЕКА 2A8, СПОСОБНОЕ НЕЙТРАЛИЗОВАТЬ ВИРУС ОСПОВАКЦИНЫ И ВИРУС ОСПЫ КОРОВ |
US7858599B2 (en) | 2005-12-30 | 2010-12-28 | Hander Robert W | Enhancement of urogenital function |
RU2317330C2 (ru) * | 2006-01-16 | 2008-02-20 | Федеральное государственное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека" | РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК pcL37, КОДИРУЮЩАЯ ПОЛИПЕПТИД СО СВОЙСТВАМИ ЛЕГКОЙ ЦЕПИ АНТИТЕЛА ЧЕЛОВЕКА ПРОТИВ ВИРУСА ОСПОВАКЦИНЫ, РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК pcH37, КОДИРУЮЩАЯ ПОЛИПЕПТИД СО СВОЙСТВАМИ ТЯЖЕЛОЙ ЦЕПИ УКАЗАННОГО АНТИТЕЛА, И ИХ ПРИМЕНЕНИЕ |
CN101020055B (zh) * | 2006-02-16 | 2012-08-08 | 中国疾病预防控制中心性病艾滋病预防控制中心 | 基于复制型痘苗病毒载体的sars疫苗 |
US9382327B2 (en) | 2006-10-10 | 2016-07-05 | Vaccinex, Inc. | Anti-CD20 antibodies and methods of use |
US7919594B2 (en) | 2007-02-14 | 2011-04-05 | Vaccinex, Inc. | Human anti-CD100 antibodies |
EP2112930B1 (en) | 2007-02-21 | 2017-01-11 | Vaccinex, Inc. | Modulation of nkt cell activity with antigen-loaded cdid molecules |
KR101642846B1 (ko) | 2007-12-26 | 2016-07-26 | 백시넥스 인코포레이티드 | 항-c35 항체 병용 치료 및 방법 |
CA2725383C (en) | 2008-05-28 | 2018-09-25 | Ruxandra Draghia-Akli | Smallpox dna vaccine and the antigens therein that elicit an immune response |
US20100081575A1 (en) | 2008-09-22 | 2010-04-01 | Robert Anthony Williamson | Methods for creating diversity in libraries and libraries, display vectors and methods, and displayed molecules |
NZ593794A (en) | 2009-01-08 | 2013-04-26 | Einstein Coll Med | Bacterial vaccines with cell wall-associated ceramide-like glycolipids and uses thereof |
JP6059013B2 (ja) | 2009-05-08 | 2017-01-11 | バクシネックス インコーポレーティッド | 抗cd100抗体およびこれを使用するための方法 |
WO2011110642A2 (en) | 2010-03-10 | 2011-09-15 | Genmab A/S | Monoclonal antibodies against c-met |
TW201134488A (en) | 2010-03-11 | 2011-10-16 | Ucb Pharma Sa | PD-1 antibodies |
JP6008842B2 (ja) | 2010-05-04 | 2016-10-19 | ファイブ プライム セラピューティックス インコーポレイテッド | Csf1rに結合する抗体 |
AU2011267869A1 (en) | 2010-06-14 | 2013-01-10 | Vaccinex, Inc. | Anti-VEGF antibodies and uses thereof |
CA2804029A1 (en) | 2010-07-07 | 2012-01-12 | Steven A. Porcelli | Ceramide-like glycolipid-associated bacterial vaccines and uses thereof |
JP6097690B2 (ja) | 2010-09-02 | 2017-03-15 | ヴァクシネックス, インコーポレイテッド | 抗cxcl13抗体およびそれを用いる方法 |
JP5925768B2 (ja) | 2011-05-13 | 2016-05-25 | 国立大学法人 東京医科歯科大学 | 骨形成促進剤 |
SG11201401458UA (en) | 2011-10-11 | 2014-07-30 | Vaccinex Inc | Use of semaphorin-4d binding molecules for modulation of blood brain barrier permeability |
US8790652B2 (en) | 2011-12-06 | 2014-07-29 | Vaccinex, Inc. | Use of the combination of semaphorin-4D inhibitory molecules and VEGF inhibitory molecules to inhibit angiogenesis |
AU2013225812B2 (en) | 2012-03-02 | 2017-11-30 | Vaccinex, Inc. | Methods for the treatment of B cell-mediated inflammatory diseases |
US9090709B2 (en) | 2012-03-28 | 2015-07-28 | Vaccinex, Inc. | Anti-SEMA4D antibodies and epitopes |
US9708601B2 (en) | 2012-04-26 | 2017-07-18 | Vaccinex, Inc. | Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus |
US10494440B2 (en) | 2012-05-11 | 2019-12-03 | Vaccinex, Inc. | Use of semaphorin-4D binding molecules to promote neurogenesis following stroke |
JP6363623B2 (ja) | 2013-01-31 | 2018-07-25 | ヴァクシネックス, インコーポレイテッド | 免疫グロブリンaのレベルを増大するための方法 |
US9371352B2 (en) | 2013-02-08 | 2016-06-21 | Vaccinex, Inc. | Modified glycolipids and methods of making and using the same |
CA2916245C (en) | 2013-06-25 | 2023-01-24 | Vaccinex, Inc. | Use of semaphorin-4d inhibitory molecules in combination with an immune modulating therapy to inhibit tumor growth and metastases |
WO2015017852A1 (en) * | 2013-08-02 | 2015-02-05 | International Park Of Creativity | Biological devices and methods of use thereof for the study and control of alzheimer's disease |
NZ630881A (en) | 2013-10-10 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treatment of atherosclerosis |
NZ630892A (en) | 2013-10-21 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treating neurodegenerative disorders |
MX2018012818A (es) | 2016-04-22 | 2019-07-04 | Vaccinex Inc | Presentacion de proteina de membrana integral en viriones envueltos extracelulares de poxvirus. |
IL264343B2 (en) * | 2016-08-02 | 2024-05-01 | Vaccinex Inc | Improved methods for generating polynucleotide libraries in cowpox/eukaryotic cells |
SG11201906670PA (en) | 2017-02-22 | 2019-08-27 | Vaccinex Inc | Early detection of glial cell activation in neurodegenerative or neuroinflammatory diseases |
JP7159187B2 (ja) | 2017-03-20 | 2022-10-24 | バクシネックス インコーポレーティッド | セマフォリン-4d抗体とエピジェネティック調節剤の組み合わせを用いたがんの処置方法 |
EP3618865A4 (en) | 2017-05-05 | 2021-05-05 | Vaccinex, Inc. | 4D ANTI-SEMAPHORIN HUMAN ANTIBODY |
-
2017
- 2017-07-31 IL IL264343A patent/IL264343B2/en unknown
- 2017-07-31 US US16/320,950 patent/US20190169606A1/en not_active Abandoned
- 2017-07-31 EP EP17837472.4A patent/EP3494131A4/en active Pending
- 2017-07-31 KR KR1020197005952A patent/KR102449406B1/ko active IP Right Grant
- 2017-07-31 WO PCT/US2017/044688 patent/WO2018026715A1/en unknown
- 2017-07-31 SG SG11201900595YA patent/SG11201900595YA/en unknown
- 2017-07-31 JP JP2019505498A patent/JP7128177B2/ja active Active
- 2017-07-31 AU AU2017306062A patent/AU2017306062B2/en active Active
- 2017-07-31 CN CN201780047905.6A patent/CN109563143A/zh active Pending
- 2017-07-31 CA CA3032512A patent/CA3032512A1/en active Pending
- 2017-07-31 MX MX2019001453A patent/MX2019001453A/es unknown
- 2017-07-31 RU RU2019105695A patent/RU2747557C2/ru active
- 2017-07-31 BR BR112019001944-8A patent/BR112019001944A2/pt unknown
-
2019
- 2019-02-28 ZA ZA2019/01286A patent/ZA201901286B/en unknown
- 2019-04-15 US US16/384,078 patent/US10640765B2/en active Active
-
2020
- 2020-04-28 US US16/860,217 patent/US20200299683A1/en not_active Abandoned
-
2022
- 2022-04-19 JP JP2022068581A patent/JP2022109946A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
RU2747557C2 (ru) | 2021-05-06 |
AU2017306062B2 (en) | 2021-12-09 |
SG11201900595YA (en) | 2019-02-27 |
RU2019105695A3 (es) | 2020-11-02 |
IL264343A (en) | 2019-02-28 |
BR112019001944A2 (pt) | 2019-05-07 |
US20190169606A1 (en) | 2019-06-06 |
JP7128177B2 (ja) | 2022-08-30 |
KR102449406B1 (ko) | 2022-09-29 |
EP3494131A4 (en) | 2020-04-15 |
CN109563143A (zh) | 2019-04-02 |
KR20190034304A (ko) | 2019-04-01 |
RU2019105695A (ru) | 2020-09-07 |
US10640765B2 (en) | 2020-05-05 |
WO2018026715A1 (en) | 2018-02-08 |
US20200299683A1 (en) | 2020-09-24 |
ZA201901286B (en) | 2023-05-31 |
EP3494131A1 (en) | 2019-06-12 |
IL264343B2 (en) | 2024-05-01 |
JP2019524126A (ja) | 2019-09-05 |
IL264343B1 (en) | 2024-01-01 |
JP2022109946A (ja) | 2022-07-28 |
AU2017306062A1 (en) | 2019-02-07 |
US20190241889A1 (en) | 2019-08-08 |
CA3032512A1 (en) | 2018-02-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2019001453A (es) | Metodos mejorados para producir genotecas de polinucleotidos en virus vacuna/ celulas eucariotas. | |
MX2017003847A (es) | Proteinas biespecificas activables por proteasas. | |
EP3474669A4 (en) | PROCESS FOR GENERATING COMBINATORY BARCODED LIBRARIES | |
PH12018500634A1 (en) | Bispecific anti-ceaxcd3 t cell activating antigen binding molecules | |
MX2021013161A (es) | Polipeptidos que contienen dominios de union de novo y usos de los mismos. | |
MX2018011941A (es) | Sistema de analisis de variantes geneticas y fenotipos y sus metodos de uso. | |
MX2021014712A (es) | Polipeptidos de transposasa y sus usos. | |
MX2023008338A (es) | Construccion de alta eficacia de bibliotecas de adn. | |
EP4333501A3 (en) | Method, computer programm and apparatus for selecting a beam for handover | |
MX2023009743A (es) | Metodos y sistemas para analisis de datos cromatograficos. | |
EP4219744A3 (en) | Methods of preparing nucleic acids for sequencing | |
IL262463A (en) | Systems and methods for finding direction using different matrices shared increased spatial example | |
WO2017098332A3 (en) | Method and system for inputting information | |
WO2014200669A3 (en) | Determining well parameters for optimization of well performance | |
MX2017013128A (es) | Sistemas y metodos para reducir densidad de los datos en grandes conjuntos de datos. | |
MX2016000463A (es) | Metodo y dispositivo para control de aplicacion. | |
WO2018094110A3 (en) | Systems and methods for identifying and expressing gene clusters | |
WO2018076024A3 (en) | Methods for screening b cell lymphocytes | |
CA2976946A1 (en) | Chemically encoded spatially addressed library screening platforms | |
EP3565132A4 (en) | WAVE BEAM SELECTION METHOD, APPARATUS, AND SYSTEM | |
EA201992476A1 (ru) | Способы идентификации соединений | |
EP3335140A4 (en) | SYSTEMS, APPARATUS AND METHODS FOR ANALYZING AND PREDICTING CELLULAR TRACKS | |
IL271089B (en) | Systems and methods for providing an ion beam | |
MX2019005622A (es) | Metodo para la preparacion de celulas de levadura electrocompetentes, y metodo para la utilizacion de dichas celulas. | |
EP3586134C0 (en) | METHODS FOR GENERATING AND SCREENING COMPARTMENTED PEPTIDE LIBRARIES |